NanHua Bio-medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
April 29, 2022 at 07:49 am EDT
Share
NanHua Bio-medicine Co., Ltd reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 64.82 million compared to CNY 33.13 million a year ago. Revenue was CNY 64.82 million compared to CNY 33.13 million a year ago. Net income was CNY 0.159904 million compared to CNY 0.957093 million a year ago. Basic earnings per share from continuing operations was CNY 0.0005 compared to CNY 0.0031 a year ago. Diluted earnings per share from continuing operations was CNY 0.0005 compared to CNY 0.0031 a year ago.
Landfar Bio medicine Co Ltd is a China-based company mainly engaged in the biomedical and energy conservation & environmental protection business. The Companyâs biomedical business includes stem cell storage and technical services, stem cell treatment research, medical instrument purchasing & sales. The Companyâs energy conservation & environmental protection business includes energy management company (EMC) contract energy management, build-transfer (BT), product sales, and sewage treatment. The Company is involved in other businesses related to aid and build project. The Company mainly conducts businesses within the domestic market.
LANDFAR BIO-MEDICINE CO., LTD 
